Compare Illumina, Inc. (ILMN) vs Strategy Inc. (MSTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Strategy Inc. — how do they compare? Illumina, Inc. trades at $191.75 (market cap $27.94B), while Strategy Inc. trades at $101.56 (market cap $35.47B). The key difference: Strategy Inc. is the larger of the two by market cap, and Illumina, Inc. is trading nearer its 52-week high, Strategy Inc. nearer its low. Which is the better fit depends on your goals.
| ILMN | MSTR | |
|---|---|---|
Market Cap | $27.94B | $35.47B |
Sector | Health | Technology |
52-Week High | $194.33 | $426.40 |
52-Week Low | $91.00 | $82.31 |
Enterprise Value | $29.33B | $50.50B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
MSTR trades at $97.77, up 3.08% today, but remains in a bearish technical trend with resistance at $98. The company shows concerning fundamentals with a -2,482% net income margin and negative cash flow from operations of -$67.24M in 2025. Recent earnings missed expectations in two of the last three quarters, though analyst consensus remains bullish with a $237.63 price target representing 143% upside potential from current levels.
While Wall Street maintains a Buy rating (62% of analysts), significant risks include extreme profitability challenges, volatile earnings history, and high debt levels. The stock's valuation appears disconnected from underlying business performance, trading at a low P/E of 5.3 but extremely high P/S of 57.4, suggesting investors are pricing in future growth that current operations don't support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Strategy Inc.
MicroStrategy Inc is a provider of enterprise analytics and mobility software. It offers MicroStrategy Analytics platform that delivers reports and dashboards and enables users to conduct ad hoc analysis and share insights through mobile devices or the Web
Read more on MSTR →
